However, iGlarLixi patients had more gastrointestinal-related adverse, primarily nausea (16.9% vs
"Although the absolute risk is low, awareness of this potential effect may help to inform treatment decisions," write the researchers
Staying Informed About Retatrutide Development As retatrutide continues through clinical development, staying informed about its progress can help you make timely decisions about access: Following Clinical Trial Results Major medical journals and pharmaceutical company press releases provide updates on trial results and regulatory submissions
Lancet 383 , 10681083 (2014)
You will then be scheduled for a consultation with our weight loss team
Managing Common Side Effects and Challenges While the injection process itself is usually quick, the way your body reacts to the medication is part of the journey